

FORM PTO/449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C24

APPLICATION NO.

09/780,669

**FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**  
(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

February 9, 2001

GROUP ART UNIT

1642

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
SM	AC	EP 679716 A1	11/02/95	EPO		
	AD	WO 99/06550	02/11/99	WIPO		
	AE	WO 00/23111	04/27/00	WIPO		
	AF	WO 00/55320	09/21/00	WIPO		
	AG	WO 01/07611	02/01/01	WIPO		
	AH	WO 01/19988	03/22/01	WIPO		

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

SM	AI	GenBank Database, Accession No. AAC17119, April 28, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	AJ	GenBank Database, Accession No. AAF08364, November 16, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	AK	GenBank Database, Accession No. AAH07290, June 29, 2004. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	AL	GenBank Database, Accession No. AF065388, April 28, 2000. Available at <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> .
	AM	GenBank Database, Accession No. AF133425, November 16, 1999. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	AN	GenBank Database, Accession No. BC000695, December 14, 2004. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C24

APPLICATION NO.

09/780,669

FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Include additional sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

February 9, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
BB			

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

54	BC	GenBank Database, Accession No. BC007290, June 29, 2004. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BD	GenBank Database, Accession No. NM_005727, October 27, 2004. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BE	GenBank Database, Accession No. NP_005718, October 27, 2004. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BF	GenBank Database, Accession No. XM_001603, July 16, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> .
	BG	GenBank Database, Accession No. XP_001603, July 16, 2001. Available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .
	BH	Geneseq Database (Thomson Derwent), Accession No. AAC99098, March 9, 2001.
	BI	Geneseq Database (Thomson Derwent), Accession No. AAX40584, June 18, 1999.
	BJ	Geneseq Database (Thomson Derwent), Accession No. AAX40605, June 18, 1999.
	BK	Geneseq Database (Thomson Derwent), Accession No. AAY11862, June 18, 1999.
✓	BL	Geneseq Database (Thomson Derwent), Accession No. AAY11883, June 18, 1999.
	BM	
	BN	

EXAMINER

DATE CONSIDERED

5/29/06

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)

DEC 2 2 2004

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C24

APPLICATION NO.

09/780,669

FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

February 9, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA	5,786,148	07/28/98	Bandman et al.	435	6	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
Sp	CB	DE 19649207	11/27/96	Germany		X
	CC	EP 317 141 A2	05/24/89	EPO		
	CD	EP 652 014 A1	05/10/95	EPO		
	CE	EP 936 270 A2	08/18/99	EPO		X
	CF	WO 93/14755	08/05/93	WIPO		
	CG	WO 93/25224	12/23/93	WIPO		
	CH	WO 94/09820	05/11/94	WIPO		
	CI	WO 95/04548	02/16/95	WIPO		
	CJ	WO 95/14772	06/01/95	WIPO (Cover page with English abstract only)		X
	CK	WO 95/30758	11/16/95	WIPO		
	CL	WO 96/21671	07/18/96	WIPO		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

su	CM	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April 1993.
	CN	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
	CO	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
	CP	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
	CQ	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	DEC 22 2004	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427C24	APPLICATION NO. 09/780,669
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANTS Jiangchun Xu et al.	
			FILING DATE February 9, 2001	GROUP ART UNIT 1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
SP	DB	WO 97/33909	09/18/97	WIPO		
	DC	WO 98/12302	03/26/98	WIPO		
	DD	WO 98/17687	04/30/98	WIPO		
	DE	WO 98/20117	05/14/98	WIPO		
	DF	WO 98/31799	07/23/98	WIPO		
	DG	WO 98/37093	08/27/98	WIPO		
	DH	WO 98/37418	08/27/98	WIPO		
	DI	WO 98/38310	09/03/98	WIPO		
	DJ	WO 98/39446	09/11/98	WIPO		
	DK	WO 98/45435	10/15/98	WIPO		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DL	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
DM	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.
DN	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
DO	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
DP	Database EMBL Accesion No. AA453562, June 5, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."

EXAMINER J. G.	DATE CONSIDERED 5/29/06
-------------------	----------------------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)

DEC 22 2004

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C24

APPLICATION NO.

09/780,669

FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

February 9, 2001

GROUP ART UNIT

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
Gu	EB	WO 98/50567	11/12/98	WIPO		
	EC	WO 99/06548	02/11/99	WIPO		
	ED	WO 99/06552	02/11/99	WIPO		
	EE	WO 99/25825	05/27/99	WIPO		
	EF	WO 99/31236	06/24/99	WIPO		
	EG	WO 00/04149	01/27/00	WIPO		
	EH	WO 01/25272	04/12/01	WIPO		
✓	EI	WO 01/34802	05/17/01	WIPO		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


Gu	EJ	Derwent Geneseq Database, Accession No. AAV58522, December 8, 1998.
	EK	Derwent Geneseq Database, Accession No. AAV61287, January 6, 1999.
	EL	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
	EM	El-Shirbiny, "Prostatic Specific Antigen," <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.
	EN	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January 1995.
✓	EO	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 $\alpha$ in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.

EXAMINER

DATE CONSIDERED

5/22/06

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427C24	APPLICATION NO. 09/780,669
 <p><b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)</p>		APPLICANTS Jiangchun Xu et al.	
		FILING DATE February 9, 2001	GROUP ART UNIT 1642

## U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FC	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
FD	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.
FE	Hillier et al., Genbank Accession No. R20590, April 18, 1995.
FF	Hudson, T., Genbank Accession No. G22461, May 31, 1996.
FG	Kroeger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
FH	Lalvani et al., "Rapid effector function in CD8 <sup>+</sup> memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.
FI	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
FJ	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
FK	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.
FL	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.

EXAMINER 	DATE CONSIDERED 5/22/06
---	----------------------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	DEC 22 2004 PATENT AND TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427C24	APPLICATION NO. 09/780,669
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANTS Jiangchun Xu et al.	
			FILING DATE February 9, 2001	GROUP ART UNIT 1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SURCLASS	FILING DATE IF APPROPRIATE
GA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
GB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GC	Nelson et al., Genbank Accession No. NP_004908, October 27, 2004.
GD	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.
GE	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, October, 1996.
GF	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.
GG	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
GH	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
GI	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291): 1371-1374, November 22, 1996.
GJ	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
GK	Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.
GL	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-449 (REV. 7-80)		DEC 22 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C24		APPLICATION NO. 09/780,669	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Jiangchun Xu et al.			
				FILING DATE February 9, 2001		GROUP ART UNIT 1642	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	HB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Sa ↓	HC	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.					
	HD	Yee et al., "Isolation of tyrosinase-specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.					
	HE	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.					
	HF						
	HG						
	HH						
	HI						
	HJ						
	HK						
	HL						
EXAMINER A. L.				DATE CONSIDERED 5/22/06			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							